Cannabis inhalation has the unique potential of increasing quality of life and mitigating disease activity besides promoting weight gain in subjects with inflammatory bowel disease (IBD), according to clinical trial data published online in the scientific journal Digestion.
The efficacy of inhaled prescription cannabis was assessed by investigators at the Chaim Sheba Medical Center in Tel Aviv, Israel in patients with long-standing IBD, such as Crohn’s disease.
Researchers reported: “After three months’ treatment, patients reported improvement in general health perception, social functioning, ability to work, physical pain and depression. A schematic scale of health perception showed an improved score. … Patients had … weight gain … during treatment and an average rise in BMI (body mass index).”
They concluded, “Three months’ treatment with inhaled cannabis improves quality of life measurements, disease activity index, and causes weight gain and rise in BMI in long-standing IBD patients.”
The study “Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study,” appeared in Digestion.